LeMaitre Vascular Sees Better Than Expected Q2 Sales, Raises $55M Via Equity At 9% Discount

Loading...
Loading...
  • LeMaitre Vascular Inc LMAT has announced preliminary Q2 2021 results and sees net sales of $40.7 million compared to an estimated $37.9 million, up 64%Y/Y on a reported basis and +35% organically.
  • It expects gross margin in the range of 65.5% to 66.1%, -2.7% at the midpoint vs. Q2 2020, due to inventory write-downs and manufacturing inefficiencies related to personnel reductions in 2020.
  • The Company sees operating income of approximately $10.9 million to $11.3 million, +128% at the midpoint.
  • The quarter ended with cash and cash equivalents of $21.8 million, and debt stood at $23 million.
  • 2Q sales growth was driven by Artegraft (acquired in June 2020) with sales of $6.7 million, as well as by valvulotomes, shunts, and allografts. 
  • Sales growth was boosted in all geographic locations, with the Americas up +83%, Europe/Middle East/Africa up +36%, and Asia/Pac up +29%. 
  • Concurrently, the Company also priced underwritten public offering of 1 million shares at $54.50 per share, with gross proceeds of approximately $54.5 million.
  • Proceeds will be used to repay senior secured credit facility and general corporate purposes.
  • Price Action: LMAT shares closed at $60.03 on Tuesday.
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareFinancingOfferingsSmall CapGeneralBriefsHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...